Back grey_arrow_rt.gif
 
Archived NATAP Articles from November 2002
 
null.gif
 
 
  1. AASLD - HCV in HIV Coinfection and in IVDUs - (11/26/02)

    2.  
  2. Magic Johnson and HIV: magical moment - (11/25/02)

    3.  
  3. Tenofovir for HBV in HIV/HBV Coinfection - (11/25/02)

    4.  
  4. 6th Intl Congress - How Low Does Your Viral Load Have To Be: Kaletra plus d4T/3TC - (11/25/02)

    5.  
  5. Lipodystrophy Workshop: Lipids and Cardiovascular Risk - Michael Dube, MD, Indiana University School of Medicine, ACTG researcher - (11/25/02)

    6.  
  6. 6th Intl Congress - Patients with HIV live longer but face new challenges - (11/21/02)

    7.  
  7. 6th Intl Congress - 48-Week Results of Study Comparing New Version of Amprenavir Once-A-Day to Nelfinavir Twice-A-Day Presented at Glasgow International HIV Meeting - (11/21/02)

    8.  
  8. Vaccine Hepatitis C - BBC NEWS WORLD ADDITION - (11/21/02)

    9.  
  9. Viread (Tenofovir) Study To Reduce HIV Transmission in Sexually Active Adults - (11/19/02)

    10.  
  10. Pegasys Plus Ribavirin Combination Therapy for Hep C is Recommended 11-0 for Approval by FDA Advisory Committee - (11/19/02)

    11.  
  11. Improved Insulin Sensitivity and Body Fat Distribution in HIV-Infected Patients Treated With Rosiglitazone: A Pilot Study - (11/19/02)

    12.  
  12. Hepatitis C Virus Viremia in HIV-Infected Individuals With Negative HCV Antibody Tests - (11/19/02)

    13.  
  13. Induction-Maintenance Study: efavirenz plus abacavir and Combivir switch to Trizivir - (11/19/02)

    14.  
  14. AASLD - HCV Viral Kinetics and Early Response Predicting Sustained Response - (11/19/02)

    15.  
  15. AASLD - IVDUs, Depression & Mental/Emotional Issues in HCV Therapy Can Be Successfully Addressed - (11/19/02)

    16.  
  16. AASLD - Treatment for Hepatitis B Looks Promising - (11/19/02)

    17.  
  17. Comparison of Methodologies for Quantification of Hepatitis C Virus (HCV) RNA in Patients Coinfected with HCV and Human Immunodeficiency Virus - Clinical Infectious Diseases 2002;35:482-487 - (11/13/02)

    18.  
  18. AASLD - Twice Weekly Injections of PegIntron - (11/13/02)

    19.  
  19. AASLD - Pegasys plus Ribavirin in African-Americans - (11/13/02)

    20.  
  20. AASLD - Hepatitis C Found In Cerebrospinal Fluid - (11/13/02)

    21.  
  21. AASLD - Orally available Hepatitis C Virus (HCV) Protease Inhibitor (BILN 2061, Boehringer Ingelheim Pharma) Demonstrates Potent Anti-viral Activity in Persons Infected with HCV Genotype 1 - Written by Mark Sulkowski, MD, Johns Hopkin University School of Medicine - (11/8/02)

    22.  
  22. AASLD - Ist HCV Protease Inhibitor: 2nd study presented at AASLD - (11/8/02)

    23.  
  23. AASLD - Hard to Treat Patients: African Americans and previous nonresponders - (11/7/02)

    24.  
  24. AASLD - Predictive Value of Early Virologic Response - (11/7/02)

    25.  
  25. AASLD - Retreatment of Nonresponders & Relapsers and Maintenance Therapy - (11/7/02)

    26.  
  26. AASLD - 1st HCV protease Inhibitor: effective over 2-day study - (11/7/02)

    27.  
  27. AASLD - Does HIV Accelerate HCV Progression? - (11/5/02)

    28.  
  28. AASLD - Liver Transplantation in HIV and HCV Coinfected Patients - (11/5/02)

    29.  
  29. AASLD - Liver Transplantation in HIV and HCV Coinfected Patients - (11/3/02)

    30.  
  30. AASLD - EPOETIN ALFA (PROCRIT) ONCE WEEKLY MAINTAINS RIBAVIRIN DOSE IN HEPATITIS C VIRUS (HCV)-INFECTED PATIENTS TREATED WITH COMBINATION THERAPY: interim results - (11/3/02)

    31.  
  31. AASLD - NEW HCV DRUGS IN EARLY DEVELOPMENT - (11/3/02)

    32.  
  32. AASLD - HCV Viral Kinetics During Therapy - (11/3/02)

    33.  
  33. NEW DRUGS - (11/3/02)

    34.  
  34. Medicaid and ADAP Access to Peginterferon and ribavirin - (11/1/02)

    35.